Collagenase clostridium histolyticum (Xiaflex)

Xiaflex is covered only for FDA‑approved indications—Dupuytren's contracture with a palpable cord (MP/PIP contracture ≥20°) and Peyronie's disease in adult men with a palpable plaque and ≥30° curvature (≥15° if prior Xiaflex)—and is not covered for non‑FDA uses. Coverage requires age ≥18, documented baseline findings and prior‑treatment history, provider experience (hand/injection for Dupuytren's; male urologic for Peyronie's), 0.58 mg per injection dosing, limits of ≤3 injections per affected cord (Dupuytren's; 3‑month approval) and ≤8 injections/4 cycles for Peyronie's with the second injection 1–3 days after the first and ~6‑week intervals between cycles (6‑month approval), and no prior complete 8‑injection course for Peyronie's.

"Dupuytren's contracture in adult patients with a palpable cord."

Sign up to see full coverage criteria, indications, and limitations.